Cargando…
Oncolytic Sendai virus-based virotherapy for cancer: recent advances
Many drugs have been developed and optimized for the treatment of cancer; however, it is difficult to completely cure cancer with anticancer drugs alone. Therefore, the development of new therapeutic technologies, in addition to new anticancer drugs, is necessary for more effective oncotherapy. Onco...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918391/ https://www.ncbi.nlm.nih.gov/pubmed/27512677 http://dx.doi.org/10.2147/OV.S66419 |
_version_ | 1782439115088723968 |
---|---|
author | Saga, Kotaro Kaneda, Yasufumi |
author_facet | Saga, Kotaro Kaneda, Yasufumi |
author_sort | Saga, Kotaro |
collection | PubMed |
description | Many drugs have been developed and optimized for the treatment of cancer; however, it is difficult to completely cure cancer with anticancer drugs alone. Therefore, the development of new therapeutic technologies, in addition to new anticancer drugs, is necessary for more effective oncotherapy. Oncolytic viruses are one potential new anticancer strategy. Various oncolytic viruses have been developed for safe and effective oncotherapy. Recently, Sendai virus-based oncotherapy has been reported by several groups, and attention has been drawn to its unique anticancer mechanisms, which are different from those of the conventional oncolytic viruses that kill cancer cells by cancer cell-selective replication. Here, we introduce Sendai virus-based virotherapy and its anticancer mechanisms. |
format | Online Article Text |
id | pubmed-4918391 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-49183912016-08-10 Oncolytic Sendai virus-based virotherapy for cancer: recent advances Saga, Kotaro Kaneda, Yasufumi Oncolytic Virother Review Many drugs have been developed and optimized for the treatment of cancer; however, it is difficult to completely cure cancer with anticancer drugs alone. Therefore, the development of new therapeutic technologies, in addition to new anticancer drugs, is necessary for more effective oncotherapy. Oncolytic viruses are one potential new anticancer strategy. Various oncolytic viruses have been developed for safe and effective oncotherapy. Recently, Sendai virus-based oncotherapy has been reported by several groups, and attention has been drawn to its unique anticancer mechanisms, which are different from those of the conventional oncolytic viruses that kill cancer cells by cancer cell-selective replication. Here, we introduce Sendai virus-based virotherapy and its anticancer mechanisms. Dove Medical Press 2015-10-01 /pmc/articles/PMC4918391/ /pubmed/27512677 http://dx.doi.org/10.2147/OV.S66419 Text en © 2015 Saga and Kaneda. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Saga, Kotaro Kaneda, Yasufumi Oncolytic Sendai virus-based virotherapy for cancer: recent advances |
title | Oncolytic Sendai virus-based virotherapy for cancer: recent advances |
title_full | Oncolytic Sendai virus-based virotherapy for cancer: recent advances |
title_fullStr | Oncolytic Sendai virus-based virotherapy for cancer: recent advances |
title_full_unstemmed | Oncolytic Sendai virus-based virotherapy for cancer: recent advances |
title_short | Oncolytic Sendai virus-based virotherapy for cancer: recent advances |
title_sort | oncolytic sendai virus-based virotherapy for cancer: recent advances |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918391/ https://www.ncbi.nlm.nih.gov/pubmed/27512677 http://dx.doi.org/10.2147/OV.S66419 |
work_keys_str_mv | AT sagakotaro oncolyticsendaivirusbasedvirotherapyforcancerrecentadvances AT kanedayasufumi oncolyticsendaivirusbasedvirotherapyforcancerrecentadvances |